Showing 103 Result(s)

Trump and Kennedy Reveal Initiative to Curb Direct-to-Consumer Pharmaceutical Advertising

Tackling Deceptive Drug Advertisements: A New Push for Transparency The pharmaceutical advertising landscape is changing. Recently, President Trump instructed Health Secretary Robert F. Kennedy Jr. to take action against misleading direct-to-consumer drug ads. This decision comes at a time when the Food and Drug Administration (FDA) is stepping up its enforcement against deceptive advertising practices. …

FDA Advisory Committees Pose a Risk to American Healthcare

Are FDA Expert Panels Jeopardizing Public Trust? The Food and Drug Administration (FDA) is a cornerstone of public health in America, guiding crucial decisions that affect our lives. However, recent developments raise serious concerns about how the agency is operating. In recent months, the FDA has started using ad-hoc “expert panels” for important decision-making processes …

FDA: U.S. pharmaceutical facility failed to adequately examine cat fur and pests

Key Takeaways Recent FDA inspections revealed serious issues at a manufacturing plant acquired by Novo Nordisk. Problems include cat hair, pests, and failures in equipment. These concerns affect not just Novo Nordisk, but also other pharmaceutical companies relying on this facility. Wall Street analysts are watching closely for potential impacts on the drug market. Historical …

FDA revokes emergency use authorization for COVID vaccines.

Key Takeaways The FDA has approved updated COVID boosters while ending emergency use authorizations for the vaccines. The changes mainly affect availability for children under 5, as vaccines will now only be available to higher-risk groups. Ongoing clinical trials are required for future approvals, aimed at ensuring safety and efficacy. Understanding the Latest Developments in …

FDA to Release Daily Updates on Drug-Related Adverse Events

FDA Now Offers Daily Updates on Adverse Drug Events The Food and Drug Administration (FDA) recently made a significant change in how it shares information about drug safety. Starting now, the FDA will publish reports on adverse events related to drugs and biological products every day. Previously, this information was only updated once every few …

The FDA should engage in global standards discussions.

The Importance of U.S. Involvement in Global Medical Standards When U.S. regulators are not part of the conversation while global medical standards are established, it carries significant risks for patient safety, medical innovation, and cybersecurity. This issue isn’t just a matter of regulations; it directly impacts the quality of healthcare we receive. Key Takeaways: U.S. …

Vinay Prasad’s Comeback and the Disruption of mRNA

Are Investors Losing Faith in mRNA Biotechs? Investors are always on the lookout for the next big thing in biotech, and mRNA technology has had its moment in the spotlight. However, recent trends suggest that enthusiasm may be waning. This week’s episode of “The Readout LOUD” dives into this topic and much more. Key Takeaways: …